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Abstract
Purpose Red cell distribution width (RDW) measures red cells’ size variability. Metastatic penile cancer displays poor 
chemotherapy response. As no validated prognostic predictor exists, we investigated whether RDW correlates independently 
with survival outcomes in metastatic penile cancer treated by chemotherapy.
Methods Electronic chemotherapy files of patients with metastatic penile cancer (M1 or N3) from a large academic supra-
regional centre were retrospectively analysed between 2005 and 2018. Patients were stratified into RDW > 13.9% and < 13.9%, 
as per published data on RDW in renal cell carcinoma. Survival time was calculated from the date of chemotherapy initiation 
until the date of death.
Results 58 patients were analysed. The RDW-high group (n = 31) had a poorer survival than the RDW-low group (n = 27). 
Median overall survival (mOS) in all patients was 19.0 months (95% CI 13.1–24.9). mOS for RDW-high was 15.0 months 
(95% CI 10.1–19.9) and 37.0 months (95% CI 32.3–43.1) for RDW-low. Kaplan–Meier curves showed a clear disparity in 
survival (log rank p = 0.025). Cox proportional hazard ratio for death, corrected for T-stage, grade, age and deprivation score 
was 0.43 (p = 0.04). Sub-analysis of the M1 patients showed mOS in RDW-high of 17 m (95% CI 11.6–22.4) vs. NR; HR for 
death of 0.42. N3 patients’ mOS in RDW-high cohort was 30 months (95% CI 4.5–55.9) vs. 13 months (95% CI 1.8–24.2) 
in RDW-low; HR for death was 0.30.
Conclusion RDW correlates independently with survival outcomes in metastatic penile cancer and may act as a potential 
predictor of survival outcomes for patients with metastatic penile cancer receiving chemotherapy.
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Introduction
Penile cancer is a rare disease with an incidence of less than 
1 per 100,000 males in Western countries such as Europe 
and North America [1]. Metastatic penile cancer with spread 
to local lymph nodes has a 5-year survival rate of approxi-
mately 59% and an even poorer 5-year survival rate of 11% 
if spread to distant regions [2]. This poor prognosis is fur-
ther compounded by the disease’s poor response rates to 
chemotherapy.
Tumour grade, as well as perineural and lymphatic inva-
sion are important prognostic indicators of penile cancer. 
The presence of nodal involvement remains the most impor-
tant indicator of survival outcome [3]. The method of obtain-
ing these indicators via biopsy is invasive. Biomarkers in 
routine blood tests of cancer patients at time of diagnosis, as 
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a tool in addition to conventional methods, may offer a mini-
mally invasive cost-effective way of improving patient strati-
fication into high and low risk subgroups to aid counselling 
and individualisation of patient care. To our knowledge, no 
validated baseline blood predictor exists for outcomes in 
stratifying patient management.
Red blood cell distribution width (RDW) is a widely 
available component of the full blood count that expresses 
the extent of the heterogeneity of erythrocyte size (anisocy-
tosis) and is calculated as a coefficient of the mean corpuscu-
lar volume (MCV) [4]. RDW has conventionally been used 
in the investigation of anaemia. As a marker of inflammation 
and anaemia, RDW will naturally reflect the general condi-
tion of the patient, including age and other co-morbidities 
[5, 6], but recent studies have assessed its independent prog-
nostic role and survival outcome in other solid and haema-
tological cancers.
Numerous studies thereafter discussed different cut-off 
levels of RDW for patient stratification in cancer care. The 
selection of a 13.9% cutoff for RDW was established in 
recently published literature on renal cell carcinoma [7] and 
non-small cell lung cancer [8] to stratify high-risk and low-
risk groups of cancer progression. Wang et al. first showed 
the correlation between RDW at the time of diagnosis and 
renal cell carcinoma stage and grade, defining advanced dis-
ease with a RDW cut-off value of 13.15% [9]. An RDW cut-
off level of 14.15% and 14.5%, respectively, have been used 
as independent factors of poor survival in epithelial ovarian 
cancer [10] and chronic lymphocytic leukaemia [11].
Typically, factors such as age, performance status and 
tumour stage are used to stratify patients according to risk 
of cancer progression and, therefore, determine treatment 
decisions. Underpinned by a paucity of clinical research 
given the rarity of this disease, a lack of robust consensus 
on whether to give treatment in both palliative and adjuvant 
setting, and if so to who, necessitates identification of ways 
to determine which patients are more likely to benefit from 
therapy and survive longer. As RDW has been implicated 
in the systemic inflammation underlying neoplastic disease, 
we, therefore, hypothesized that RDW levels might be an 
easily accessible marker associated with progression and 
overall survival in patients with metastatic penile cancer 
receiving chemotherapy.
Methods
The electronic medical records of 1777 patients with penile 
cancer in a large academic supra-regional centre for penile 
cancer were retrospectively analysed, with dates of refer-
ral ranging from June 2001 to March 2018. From this large 
dataset, 75 patients with a diagnosis of metastatic penile 
cancer—defined by our group as either M1 disease or N3 
disease, receiving palliative or adjuvant chemotherapy, were 
identified. A further 17 patients were excluded as the data 
on date of diagnosis or baseline haematology results were 
not available. The final cohort included 58 patients diag-
nosed between April 2005 and March 2018. The diagnosis 
of penile cancer was confirmed pathologically with biopsy.
The following variables were included to assess the prog-
nostic role of RDW: age at time of diagnosis, chemotherapy 
regimen, histopathology, staging, date of progression, date 
of death, baseline and pre-cycle full blood count. In addition, 
patient deprivation scores from the national Index of Mul-
tiple Deprivation were collected. Patients were divided into 
two groups according to a baseline (first blood result after 
referral) RDW cut-off value established in previously dis-
cussed published renal cell carcinoma data [11]: RDW-low 
(< 13.9%) and RDW-high (> 13.9%). The reference range for 
normal RDW in St George’s University Hospital laboratory 
is 11.5–15.0%. Survival time was calculated from the date 
of chemotherapy initiation until the date of death or the date 
of the last consultation. Statistical analysis was carried out 
using SPSS Ver. 25 Software. Cox regression analysis was 
performed to assess hazard ratios for death and results were 
corrected for stage, grade, age, anaemia and social depriva-
tion score. The Kaplan Meier method was used to analyse 
the relationship between the two RDW group’s survival 
times with log rank testing.
Results
58 patients were analysed post exclusion. 43 were M1 
(metastatic disease to distant sites outside of the pelvic 
lymph nodes) and 15 were N3 (positive pelvic lymph node 
disease—who received adjuvant chemotherapy). Median 
follow-up was for 449 days (interquartile range 187–797). 
Follow-up was for a maximum of 3275 days (9 years). 
30 (51.7%) patients died during this follow-up period. 11 
patients from the RDW-low group (40.7%) and 19 patients 
from the RDW-high group (61.3%) died. Patient demograph-
ics, chemotherapy regimens and histopathology of the low 
and high RDW subgroups are displayed in Table 1. Table 2 
shows components of patients’ pre-treatment full blood 
count.
Patients in the RDW-high group (n = 31) had a poorer 
survival than the RDW-low group (n = 27) (Fig. 1a). Median 
overall survival (mOS) in the whole group was 19.0 months 
(95% CI 13.1–24.9). For RDW-high mOS was 15.0 months 
(95% CI 10.1–19.9) and for RDW-low it was 37.0 months 
(95% CI 32.3–43.1). Kaplan–Meier curves show a clear 
disparity in survival (log rank p = 0.025), and Cox propor-
tional hazard ratio for death, corrected for T-stage, grade, 
age, anaemia and deprivation score was 0.43 (p = 0.04) 
(Fig. 1a). When patients were sub-analysed, those receiving 
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adjuvant chemotherapy had a mOS in the RDW-high cohort 
of 30 months (95% CI 4.1–55.9), vs. a mOS in the RDW-low 
cohort of 13 months (95% CI 1.8–24.2) (Fig. 1b). The haz-
ard ratio for death in this cohort was 0.30. In the palliative 
chemotherapy group, mOS in the RDW-high cohort was 
17 months (95% CI 11.6–22.4), with those in the RDW-low 
cohort not reaching median (NR) (Fig. 1c). Hazard ratio for 
death, when corrected for T-stage, grade, age, anaemia and 
deprivation score was 0.42.
Discussion
To our knowledge, this is the first work done on the associa-
tion between RDW and survival outcomes in patients with 
metastatic penile cancer. The key finding is that in metastatic 
penile cancer, patients with a high RDW value before ini-
tiation of systemic therapy were associated with advanced 
disease and, therefore, had a poorer survival than patients 
with low RDW values. We took steps to address the potential 
Table 1  Baseline patient 
demographics, chemotherapy 
regimes and histopathology 
stratified according to RDW 
level
RDW-low (< 13.9%; n = 27), 
n (%)
RDW-high 
(> 13.9%; n = 31), 
n (%)
Median age (range) 57 (31–83) 63 (43–80)
Socioeconomic status (IMD quintiles)
 I 2 (3.4%) 4 (6.9%)
 II 8 (29.6%) 9 (29.0%)
 III 5 (18.5%) 2 (6.5%)
 IV 7 (25.9%) 6 (19.4%)
 V 3 (11.1%) 10 (32.3%)
 Other 2 (7.4%) 0 (0.0%)
First-line therapy
 Cisplatin + capecitabine 10 (17.2%) 15 (25.9%)
 VinCaP (vinflunine) 1 (1.7%) 1 (1.7%)
 TIP (paclitaxel + isosfamide + cisplatin) 0 (0.0%) 1 (1.7%)
 Carboplatin + methotrexate + bleomycin 0 (0.0%) 1 (1.7%)
 TPF (docetaxel + cisplatin + 5-FU) 2 (3.4%) 1 (1.7%)
 Other 14 (24.1%) 12 (20.7%)
pT stage
 1 5 (18.5%) 5 (16.1%)
 2 13 (48.1%) 11 (35.5%)
 3 8 (29.6%) 10 (32.3%)
 4 1 (3.7%) 2 (6.5%)
 Unknown 0 (0.0%) 3 (9.7%)
pN stage
 0 2 (7.4%) 2 (6.5%)
 1 5 (18.5%) 4 (12.9%)
 2 6 (22.2%) 8 (25.8%)
 3 5 (18.5%) 5 (16.1%)
 Unknown 9 (33.3%) 12 (38.7%)
Grade
 1 0 (0.0%) 0 (0.0%)
 2 4 (14.8%) 5 (16.1%)
 3 23 (85.2%) 22 (71.0%)
 Other 0 (0.0%) 4 (13.0%)
Table 2  Pre-treatment full blood count
RDW-low (< 13.9%; 
n = 27), median 
(range)
RDW-high (> 13.9%; 
n = 31), median (range)
Haemoglobin (g/L) 141 (104–163) 112 (77–152)
Platelets  (109/L) 298 (68–492) 303 (176–817)
Neutrophils  (109/L) 5.7 (1.8–12.8) 6.4 (2.1–21.4)
Lymphocytes 
 (109/L)
2.0 (1.0–3.2) 1.2 (0.4–2.4)
RDW (%) 12.9 (11.8–13.8) 14.7 (13.9–23.9)
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confounding effects of higher stage, grade and lower hae-
moglobin in the poorer prognosis group, by stratifying our 
patients in the Cox regression analyses to obtain hazard 
ratios for death corrected for stage, grade, age, anaemia and 
socio-economic deprivation, thus identifying RDW as an 
independent biomarker in this setting.
Work on prognostic indicators in penile cancer has added 
to the way in which patients can be stratified and managed. 
High levels of RDW and other inflammatory markers have 
been implicated with aggressive cancers that show poor 
chemotherapy response. Similar results were noted in renal 
cell carcinoma treated with partial and radial nephrectomy 
according to an RDW cut-off of 13.9%, concluding that pre-
operative levels can aid in assessing the tumour aggressive-
ness [7]. The use of RDW as a prognostic indicator in cancer 
has been re-iterated in a meta-analysis of 17 studies across 
a number of tumour types, including lung and oesophageal 
cancer [12]. Furthermore, the Tromso Study demonstrated 
that elevated pre-treatment levels correlated to unfavourable 
pathological prognostic factors, such as tumour size, grade 
and lymph node involvement [13]. They found that a small 
1% increase in RDW was associated with a significant rise in 
the risk of regional cancer spread by 21% and distal metas-
tases by 19% [13]. Interestingly, RDW could possibly be 
monitored for changes after several cycles of chemotherapy 
to assess for treatment response [14].
Systemic inflammation plays an important role in the 
progression of cancer, with emerging evidence that simple 
inflammatory markers in the full blood count can aid clini-
cians in targeting and monitoring treatment. Pre-treatment 
neutrophil–lymphocyte ratio (NLR), which uses two readily 
available components of the full blood count, has extensively 
been investigated as an independent prognostic indicator of 
poor survival in other solid urological malignancies, such 
as renal cell carcinoma and upper tract urothelial carcinoma 
[15–17]. In addition, a high pre-treatment CRP value greater 
than 15 mg/L was associated with advanced staging, greater 
metastatic spread and a poorer 5-year survival outcome in 
penile cancer [18]. However, their use in clinical practice is 
Fig. 1  a Kaplan-Meier plot of median overall survival between 
RDW-high and RDW-low groups for all patients. b Kaplan-Meier 
plot of median overall survival between RDW-high and RDW-low 
groups for patients receiving adjuvant chemotherapy. c Kaplan-Meier 
plot of median overall survival between RDW-high and RDW-low 
groups for patients receiving palliative chemotherapy
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limited when monitoring a patient’s cancer progression, or 
indeed their baseline risk of death.
The underlying mechanism between RDW and cancer 
progression is not clearly understood. A high RDW may 
be driven by the excessive production of cytokines in the 
tumour microenvironment, such as IL-6 and TNF-a [19, 
20]. However, it is difficult to clarify whether a high RDW 
level is due to the systemic inflammatory process or the 
poor chemotherapy response [21]. Chronic inflamma-
tion impairs iron metabolism and elevated RDW may be 
closely associated with inadequate erythropoeisis as part 
of the natural ageing process amongst cancer patients [22]. 
A high RDW level in cancer patients may also be associ-
ated with anaemia and poor nutritional status. In addition, 
RDW has been implicated with poor survival outcomes in 
patients showing signs of cachexia [21, 23, 24].
Due to the low incidence of the disease and the speci-
ficity of our inclusion criteria, one of the main limita-
tions is that the study findings can only apply to patients 
with metastatic penile cancer receiving palliative or adju-
vant chemotherapy and, therefore, cannot be used in the 
stratification of patients undergoing other forms of cancer 
therapy, such as surgery and radiotherapy. Furthermore, 
a significant proportion of patients were excluded from 
this analysis due to a lack of sufficient baseline laboratory 
results. Moreover, RDW was not adjusted for confounding 
factors such as cardiovascular disease and infections that 
may influence the RDW level. We did, however, take steps 
in correcting our findings for a number of other potential 
confounders. As an important next step, we would recom-
mend validation of the findings of the present study in a 
separate cohort.
Conclusion
As penile cancer is rare, there is little data available on 
biomarkers of response to aid individualisation of patient 
therapy. Our data suggests that high pre-treatment RDW 
can be used as a potential predictor of unfavourable survival 
outcomes for patients with metastatic penile cancer receiv-
ing chemotherapy. This inexpensive widely-available blood 
marker of inflammation could possibly be used in the clini-
cal setting to stratify patients into high and low risk groups 
of metastatic penile cancer progression and, therefore, aid in 
the decision-making process regarding their treatment path-
way; however, further validation is required. This finding 
also raises the possibility that RDW normalisation could be 
used as a tool to assess the efficacy of chemotherapy cycles 
in penile cancer, and this is an area warranting further 
investigation.
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